Nachtnebel, A. (2010): Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer. DSD: Horizon Scanning in Oncology 09.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
First-line therapy with lapatinib in the advanced/metastatic breast cancer setting was assessed in two phase III trials. Progression-free survival was improved by about 5 months in HER2 and hormone receptor positive women but similar data for gains in overall survival are still missing. Hence, it seems that the primary benefit of orally administered lapatinib is the potential of delaying more aggressive therapies with considerable toxicities in a well-defined hormone receptor/HER2 positive population.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||cancer, lapatinib, tyrosine kinase inhibitor, oncology|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
WP Gynaecology > WP 800-910 Breast
QZ Pathology > QZ 200-380 Neoplasms.Cysts
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||DSD: Horizon Scanning in Oncology 09|
|Deposited on:||14 Jul 2010 12:38|
|Last Modified:||14 Jul 2010 12:38|
Repository Staff Only: item control page